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INTRODUCTION
This chapter makes treatment recommendations for GN
mediated by antibodies against the GBM (i.e., anti-GBM GN)
whether or not it is associated with pulmonary hemorrhage
(Goodpasture’s disease). The cost implications for global
application of this guideline are addressed in Chapter 2.
14.1: Treatment of anti-GBM GN
14.1.1: We recommend initiating immunosuppression
with cyclophosphamide and corticosteroids
plus plasmapheresis (see Table 31) in all
patients with anti-GBM GN except those who
are dialysis-dependent at presentation and have
100% crescents in an adequate biopsy sample,
and do not have pulmonary hemorrhage. (1B)
14.1.2: Start treatment for anti-GBM GN without
delay once the diagnosis is confirmed. If the
diagnosis is highly suspected, it would be
appropriate to begin high-dose cortico-
steroids and plasmapheresis (Table 31) while
waiting for confirmation. (Not Graded)
14.1.3: We recommend no maintenance immuno-
suppressive therapy for anti-GBM GN. (1D)
14.1.4: Defer kidney transplantation after anti-GBMGN
until anti-GBM antibodies have been undetect-
able for a minimum of 6 months. (Not Graded)
BACKGROUND
Anti-GBM GN is generally a fulminant and rapidly progressive
disease that is caused by autoantibodies to the noncollagenous
domain of the a3 chain of type IV collagen. Anti-GBM GN is
relatively rare, with an estimated annual incidence of 0.5-1 per
million population. It can present as an isolated GN, or as a
pulmonary-renal syndrome with severe lung hemorrhage.
Prior to the introduction of intense immunosuppression for
anti-GBM GN, patient survival was very poor. Although
mortality has improved, kidney survival remains poor,
possibly because of delays in making the diagnosis and
initiating treatment. The strategy for treating anti-GBM GN is
to remove the pathogenic autoantibodies from the circulation,
and simultaneously prevent further autoantibody production
and attenuate existing glomerular inflammation and injury.
RATIONALE
K Patient and kidney survival in untreated anti-GBM GN is
poor.
K There is moderate-quality evidence that intense immuno-
suppression plus plasmapheresis improves patient and
kidney survival; this evidence comes from one small RCT,
one large, and several smaller retrospective series. All of
these studies demonstrate good patient survival and
moderate kidney survival, providing a compelling ratio-
nale to use immunosuppression and plasmapheresis.
K Many patients at presentation have severe kidney failure,
and require dialysis. This is usually correlated with the
number of glomeruli that show crescents on kidney biopsy.
Despite intense immunosuppression, patients who are
dialysis-dependent at the start of treatment and have
85–100% glomerular crescents do not recover kidney
function, and generally will require long-term RRT.
K Because the progression of anti-GBM GN can be very
rapid, and outcome is related to the severity at
presentation, it is appropriate to start treatment im-
mediately with high-dose corticosteroids. After the
diagnosis is confirmed, cyclophosphamide and plasma-
pheresis must be started. Patients should be free of
infection or receiving appropriate antimicrobial therapy.
K Patients with pulmonary hemorrhage as well as anti-
GBM GN (Goodpasture’s disease) should receive treat-
ment with corticosteroids, cyclophosphamide, and plas-
mapheresis, even in the setting of severe kidney failure
and extensive glomerular crescent formation. Without
such therapy, Goodpasture’s disease has a very high
mortality. There is, however, no definite evidence that
plasmapheresis is beneficial when there are only minor
clinical signs of pulmonary hemorrhage.
K Because anti-GBM antibodies are pathogenic, it is
prudent to wait until they are undetectable before
considering a kidney transplant for those with ESRD.
As the pathogenesis of anti-GBM GN became clear,
treatment regimens were designed to remove the circulating
pathogenic antibody that caused the disease, suppress further
synthesis of this pathogenic antibody, and attenuate the
glomerular inflammatory response initiated by the anti-GBM
antibody. The best summary of this approach is a large
retrospective study of anti-GBM GN from the Hammersmith
Hospital,740 including 85 patients seen over 25 years. Seventy-
one patients were treated with high-dose prednisone*
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*Prednisone and prednisolone are interchangeable according to local
practice, with equivalent dosing.
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(1 mg/kg/d) tapered over 6–9 months, oral cyclophosphamide
for 2–3 months, and daily plasmapheresis for 14 days,
or until the anti-GBM antibody was no longer detectable.
The kidney outcome for this cohort was influenced by kidney
function at presentation. Patients who had an initial
SCr o5.7 mg/dl (o504 mmol/l) had a 1-year overall survival
of 100% and a kidney survival of 95%, and at 5 years patient
and kidney survival were both 94%. If the initial SCr was
45.7 mg/dl (4504 mmol/l) but dialysis was not required
immediately, the patient and kidney survivals were 83% and
82% at 1 year, and 80% and 50% at 5 years, respectively.
However, among patients who needed dialysis at presenta-
tion, patient and kidney survival were reduced to 65% and
8% at 1 year, and 44% and 13% at 5 years, respectively.
Compared to nearly 100% mortality from pulmonary
hemorrhage and kidney failure in historical series, this
treatment strategy represented a significant improvement.
The role of plasmapheresis in addition to immuno-
suppression has been questioned, and was tested in a small
RCT (n¼ 17).741 Although this study used prednisone and
cyclophosphamide for immunosuppression, there were slight
differences in dose and duration compared to the Hammer-
smith study. Most importantly, plasmapheresis was done
every 3 days instead of daily and a mean of nine treatments
was completed. All patients received prednisone and
cyclophosphamide, and half were randomized to additional
plasmapheresis. In those receiving plasmapheresis, anti-
GBM antibodies disappeared about twice as fast as in the
control group (all within 50 days, P o0.05). At the end of
therapy, SCr in those receiving plasmapheresis was 4.1±
0.5 mg/dl (362±44 mmol/l) compared to 9.2±0.7 mg/dl
(813±62 mmol/l) in the controls (Po0.05); only two patients
receiving plasmapheresis needed chronic dialysis vs. six in the
controls. Although the two treatment groups were well-
matched clinically at the beginning of the study, kidney
biopsies showed a higher percentage of glomerular crescents
in controls. Because of this difference in histology and the
small study size, the evidence for better kidney outcome with
plasmapheresis cannot be regarded as definitive.
Anti-GBM antibody titers should be regularly monitored.742
Plasmapheresis may be stopped when the circulating anti-
body is no longer detectable, usually after 10–14 treat-
ments. Corticosteroids have generally been continued for at
least 6 months, and cyclophosphamide for 2–3 months. This
immunosuppression must be sufficient both to prevent further
antibody production, and to treat kidney inflammation.
About 20–30% of patients with anti-GBM disease will
also have ANCA, usually with anti-MPO specificity, but
the double-antibody–positive patients do not appear to have
a different prognosis or disease course, according to most
studies.743–747
The outcomes of the Hammersmith cohort740 are repre-
sentative of what can be expected with a uniform, aggressive
approach to therapy as outlined. In other series of anti-
GBM GN, not all necessarily using the same treatment
regimens, and encompassing patients from the USA, Europe,
China, and Japan, patient survival at 6–12 months was
approximately 67–94%, and kidney survival was about
15–58%.619,741,745,748,749
The predictors of kidney survival in anti-GBM GN are
SCr at presentation, the need for dialysis at presentation, and
the percentage of glomerular crescents.740,741,743 In two
studies, patients with an initial SCr 45.7 mg/dl (4504
mmol/l) or 9.7 mg/dl (858 mmol/l) all became chronically
dialysis-dependent despite aggressive treatment.744,747 Two
studies found that patients who required dialysis at presen-
tation were never able to come off dialysis, despite aggressive
treatment.744,745 The most optimistic study observed that all
patients with a combination of dialysis at presentation plus
100% crescents on kidney biopsy never recovered kidney
function sufficiently to come off dialysis.740 A survey of
several studies shows dialysis dependence at diagnosis in a
median of 55% (range 12–83%) of patients, 100% crescents
on kidney biopsy in 20.5% (range 7–50%) of patients, and a
median initial SCr of 6.9 mg/dl (610 mmol/l) (range 4.9–
7.2 mg/dl [433–637 mmol/l]), underscoring the importance of
early diagnosis and intervention.740,741,744,745,747–750 These
findings, along with the patient’s general condition, will help
in deciding how aggressive to be in treating the kidney
manifestations of anti-GBM GN. However, in the presence of
pulmonary hemorrhage, aggressive treatment should be
undertaken, regardless of the kidney prognosis.751
In contrast to most other autoimmune kidney diseases,
anti-GBM GN is not characterized by a frequently relapsing
course; the autoantibodies seem to disappear spontaneously
after 12–18 months.752 Nonetheless, relapses of anti-GBM
Table 31 | Therapy of anti-GBM GN
Corticosteroids
Week Prednisone dose
0–2 Methylprednisolone 500–1000mg/d i.v. for
3 days, followed by prednisone, 1mg/kg/d
IBW (maximum 80mg/d)
2–4 0.6mg/kg/d
4–8 0.4mg/kg/d
8–10 30mg/d
10–11 25mg/d
11–12 20mg/d
12–13 17.5mg/d
13–14 15mg/d
14–15 12.5mg/d
15–16 10mg/d
16– IBW o70 kg: 7.5mg/d
IBW Z70 kg: 10mg/d
Discontinue after
6 months
Cyclophosphamide: 2mg/kg/d orally for 3 months.
Plasmapheresis: One 4-liter exchange per day with 5% albumin. Add 150–300ml
fresh frozen plasma at the end of each pheresis session if patients have pulmonary
hemorrhage, or have had recent surgery, including kidney biopsy. Plasmapheresis
should be continued for 14 days or until anti-GBM antibodies are no longer
detectable.
GBM, glomerular basement membrane; GN, glomerulonephritis; IBW, ideal body
weight.
There is no evidence to support these dosing schedules, which are based on
regimens associated with good outcome in observational studies.
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GN have been reported in the literature, can manifest as
recurrent clinical kidney disease or pulmonary hemorrhage,
and are often associated with a reappearance of circulating
anti-GBM antibodies.752–755 It has been estimated that the
mean time to recurrence is 4.3 years, with a range of 1–10
years, and that late recurrences may occur with a frequency of
2–14%.748,752,754 Retreatment with intense immunosuppres-
sion and plasmapheresis is generally successful in re-inducing
remission.752
There is very little information on the treatment of
refractory anti-GBM GN. Some case reports have used MMF
or rituximab, but no firm recommendation can be made.
There is very little evidence as to the timing of transplant
after anti-GBM disease has caused ESRD. Most transplant
centers require at least 6 months of undetectable anti-
GBM antibody levels before kidney transplantation.756,757
Recurrent anti-GBM disease in a kidney allograft is very
unusual.756,757
RESEARCH RECOMMENDATIONS
K A study is needed to compare rituximab to cyclophos-
phamide, both combined with prednisone plus plasma-
pheresis for induction of remission.
K A study is needed to compare MMF plus prednisone
plus plasmapheresis to standard treatment—cyclophos-
phamide plus prednisone plus plasmapheresis—for
induction of remission.
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